EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Late-Onset Cold Agglutinin Syndrome Following Nivolumab Therapy: A Delayed Immune-Related Adverse Event with Masked Hemolysis – A Case Report

Hüseyin İflazoğlu, Volkan İnal

Case Reports in Oncology · 2026-08-22 · 19 (1) · 1485-1492

DOI: 10.1159/cro/abzag012 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Cold agglutinin syndrome (CAS) is a secondary form of cold antibody-mediated autoimmune hemolytic anemia. Immune checkpoint inhibitor-associated CAS is exceedingly uncommon and poses particular diagnostic challenges in critically ill patients. Case Presentation: A 66-year-old male with metastatic squamous cell lung carcinoma was admitted to the intensive care unit (ICU) for respiratory failure, with a course complicated by sepsis and continuous renal replacement therapy (CRRT). On ICU day 24, hemoglobin-hematocrit (Hb-Hct) discordance was identified; peripheral blood smear confirmed erythrocyte agglutination. Direct antiglobulin testing (DAT) revealed C3d positivity with negative IgG, and the cold agglutinin titer was 1/64. Total and indirect bilirubin were elevated. Quantitative immunoglobulin concentrations did not demonstrate an elevated IgM level; however, serum protein electrophoresis, immunofixation, and bone marrow examination could not be completed, so an occult clonal B-cell disorder could not be definitively excluded. The clinical presentation was considered more consistent with probable secondary CAS than with primary cold agglutinin disease (CAD). CAS was diagnosed as a delayed immune-related adverse event (irAE) approximately 14 months after nivolumab discontinuation. No recognized infectious trigger classically associated with cold agglutinin-mediated hemolysis was identified. A malignancy-associated mechanism could not be completely excluded but was considered less likely. Causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale (score: 6; probable adverse drug reaction). Rituximab was withheld due to refractory sepsis and hemodynamic instability. Management consisted of active thermal control (CRRT circuit temperature maintained at 38°C), warmed erythrocyte transfusions, and avoidance of cold exposure. Conclusion: This case highlights that CAS may emerge as a delayed irAE following nivolumab therapy. Hb-Hct discordance should be recognized as an early diagnostic clue when classical hemolytic markers are masked. Active thermal control during CRRT represents a practical strategy to limit hemolysis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →